RGS2 expression and aldosterone: Renin ratio modulate response to drug therapy in hypertensive patients

Journal of Hypertension

Volumn 28, Issue 5, 2010, Pages 1104-1108

  Semplicini, Andrea ^a   Strapazzon, Giacomo ^a   Papparella, Italia ^a   Sartori, Michelangelo ^a   Realdi, Anna ^a   MacChini, Luisa ^a   Calò, Lorenzo A ^a   Ceolotto, Giulio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Aldosterone; Angiotensin II; Antihypertensive therapy; G protein; Resistant hypertension; RGS2

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; RENIN; RGS2 PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

EID: 77951298152     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328339930f     Document Type: Article

References (33)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of theCouncil for High BloodPressureResearch. Hypertension 2008; 51:1403-1419.
2. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR, RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18:619-626.
3. Kaplan NM. Resistant hypertension. J Hypertens 2005; 23:1441-1444. (Pubitemid 41104810)
4. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006; 355:385-392.
5. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
6. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816. (Pubitemid 37509488)
7. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345:479-486. (Pubitemid 32758499)
8. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003; 111:445-452. (Pubitemid 36228001)
9. Semplicini A, Lenzini L, Sartori M, Papparella I, Calo LA, Pagnin E, et al. Reduced expression of regulator of G-protein signalling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24:1115-1124. (Pubitemid 43772320)
10. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053. (Pubitemid 36667855)
11. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319:630-635. (Pubitemid 29414567)
12. Ceolotto G, Gallo A, Sartori M, Valente R, Baritono E, Semplicini A, et al. Hyperglycemia acutely increases monocyte extracellular signal-regulated kinase activity in vivo in humans. J Clin Endocrinol Metab 2001; 86:1301-1305. (Pubitemid 32323020)
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res 2001; 29:e45.
14. Kehrl JH, Sinnarajah S. RGS2: a multifunctional regulator of G-protein signalling. Int J Biochem Cell Biol 2002; 34:432-438. (Pubitemid 34242757)
15. Le TH, Coffman TM. RGS2: a 'turn-off' in hypertension. J Clin Invest 2003; 111:441-443.
16. Wieland T, Lutz S, Chidiac P. Regulators of G protein signalling: a spotlight on emerging functions in the cardiovascular system. Curr Opin Pharmacol 2007; 7:201-207. (Pubitemid 46404739)
17. Calò LA, PagninE, Davis PA, Sartori M,CeolottoG, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89:4153-4157. (Pubitemid 39071528)
18. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26:938-945. (Pubitemid 351520981)
19. Grant SL, Lassegue B, Griendling KK, Ushio-Fukai M, Lyons PR, Alexander RW. Specific regulation of RGS2 messenger RNA by angiotensin II in cultured vascular smooth muscle cells. Mol Pharmacol 2000; 57:460-467. (Pubitemid 30140875)
20. Romero DG, Plonczynski MW, Gomez-Sanchez EP, Yanes LL, Gomez-Sanchez CE. RGS2 is regulated by angiotensin II and functions as a negative feedback of aldosterone production in H295R human adrenocortical cells. Endocrinology 2006; 147:3889-3897.
21. Li Y, Hashim S, Anand-Srivastava MB. Angiotensin II-evoked enhanced expression of RGS2 attenuates Gi-mediated adenylyl cyclase signaling in A10 cells. Cardiovasc Res 2005; 66:503-511. (Pubitemid 40725762)
22. Quiñ ones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol 1997; 10:188-191. (Pubitemid 27333194)
23. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens 2003; 12:511-516. (Pubitemid 37083111)
24. Semplicini A, Ceolotto G, Sartori M, Maresca A, Baritono E, De Toni R, et al. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide. J Nephrol 2002; 15:489-496. (Pubitemid 35396512)
25. Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 2005; 16:1909-1919. (Pubitemid 41716421)
26. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66:1465-1470. (Pubitemid 39298378)
27. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896. (Pubitemid 35434912)
28. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699-705.
29. Sartori M, Calo LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006; 19:373-379.
30. Fejes-Toth G, Naray-Fejes-Toth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology 2007; 148:1502-1510. (Pubitemid 46457129)
31. Acelajado MC, Calhoun DA. Resistant hypertension: who and how to evaluate. Curr Opin Cardiol 2009; 24:340-344.
32. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
33. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens 2002; 20:593-596.